146 related articles for article (PubMed ID: 19212818)
1. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib.
Vroling L; van der Veldt AA; de Haas RR; Haanen JB; Schuurhuis GJ; Kuik DJ; van Cruijsen H; Verheul HM; van den Eertwegh AJ; Hoekman K; Boven E; van Hinsbergh VW; Broxterman HJ
Angiogenesis; 2009; 12(1):69-79. PubMed ID: 19212818
[TBL] [Abstract][Full Text] [Related]
2. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
Deprimo SE; Bello CL; Smeraglia J; Baum CM; Spinella D; Rini BI; Michaelson MD; Motzer RJ
J Transl Med; 2007 Jul; 5():32. PubMed ID: 17605814
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer.
van der Veldt AA; Vroling L; de Haas RR; Koolwijk P; van den Eertwegh AJ; Haanen JB; van Hinsbergh VW; Broxterman HJ; Boven E
Int J Cancer; 2012 Aug; 131(4):E484-93. PubMed ID: 21953673
[TBL] [Abstract][Full Text] [Related]
4. Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.
Farace F; Gross-Goupil M; Tournay E; Taylor M; Vimond N; Jacques N; Billiot F; Mauguen A; Hill C; Escudier B
Br J Cancer; 2011 Mar; 104(7):1144-50. PubMed ID: 21386843
[TBL] [Abstract][Full Text] [Related]
5. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
Harmon CS; DePrimo SE; Figlin RA; Hudes GR; Hutson TE; Michaelson MD; Négrier S; Kim ST; Huang X; Williams JA; Eisen T; Motzer RJ
Cancer Chemother Pharmacol; 2014 Jan; 73(1):151-61. PubMed ID: 24220935
[TBL] [Abstract][Full Text] [Related]
6. Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib.
Powles T; Chowdhury S; Shamash J; Bazeos A; Gillessen S; Saunders N; Lim L; Sarwar N; Sadev A; Wilson P; Nathan P; Boleti K; Peters J; Agrawal S
Ann Oncol; 2011 Apr; 22(4):815-820. PubMed ID: 20943595
[TBL] [Abstract][Full Text] [Related]
7. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients.
Porta C; Paglino C; Imarisio I; Ganini C; Sacchi L; Quaglini S; Giunta V; De Amici M
Oncology; 2013; 84(2):115-22. PubMed ID: 23154434
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
9. NGAL can alternately mediate sunitinib resistance in renal cell carcinoma.
Yu DS; Wu CL; Ping SY; Huang YL; Shen KH
J Urol; 2014 Aug; 192(2):559-66. PubMed ID: 24423438
[TBL] [Abstract][Full Text] [Related]
10. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
Norden-Zfoni A; Desai J; Manola J; Beaudry P; Force J; Maki R; Folkman J; Bello C; Baum C; DePrimo SE; Shalinsky DR; Demetri GD; Heymach JV
Clin Cancer Res; 2007 May; 13(9):2643-50. PubMed ID: 17473195
[TBL] [Abstract][Full Text] [Related]
11. The Surge in the Number of Circulating Tumor Cells Following Treatment with Sunitinib for Metastatic Renal Cell Carcinoma.
Nagaya N; Kanayama M; Nagata M; Horie S
Intern Med; 2018 Sep; 57(18):2695-2700. PubMed ID: 29709937
[TBL] [Abstract][Full Text] [Related]
12. VEGFR2 expressing circulating (progenitor) cell populations in volunteers and cancer patients.
Vroling L; Yuana Y; Schuurhuis GJ; van Hinsbergh VW; Gundy C; de Haas R; van Cruijsen H; Boven E; Hoekman K; Broxterman HJ
Thromb Haemost; 2007 Aug; 98(2):440-50. PubMed ID: 17721629
[TBL] [Abstract][Full Text] [Related]
13. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
Motzer RJ; Michaelson MD; Redman BG; Hudes GR; Wilding G; Figlin RA; Ginsberg MS; Kim ST; Baum CM; DePrimo SE; Li JZ; Bello CL; Theuer CP; George DJ; Rini BI
J Clin Oncol; 2006 Jan; 24(1):16-24. PubMed ID: 16330672
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.
Maita S; Yuasa T; Tsuchiya N; Mitobe Y; Narita S; Horikawa Y; Hatake K; Fukui I; Kimura S; Maekawa T; Habuchi T
Int J Cancer; 2012 Feb; 130(3):677-84. PubMed ID: 21387300
[TBL] [Abstract][Full Text] [Related]
15. [The changes in complete blood count in patients treated with sunitinib malate for metastatic clear cell renal cell carcinoma].
Kucharz J; Michałowska-Kaczmarczyk A; Streb J; Kuzniewski M; Herman RM; Krzemieniecki K
Przegl Lek; 2013; 70(9):712-4. PubMed ID: 24455830
[TBL] [Abstract][Full Text] [Related]
16. Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib.
Gruenwald V; Beutel G; Schuch-Jantsch S; Reuter C; Ivanyi P; Ganser A; Haubitz M
BMC Cancer; 2010 Dec; 10():695. PubMed ID: 21194438
[TBL] [Abstract][Full Text] [Related]
17. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels.
Kappers MH; van Esch JH; Sluiter W; Sleijfer S; Danser AH; van den Meiracker AH
Hypertension; 2010 Oct; 56(4):675-81. PubMed ID: 20733093
[TBL] [Abstract][Full Text] [Related]
18. Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.
Duignan IJ; Corcoran E; Pennello A; Plym MJ; Amatulli M; Claros N; Iacolina M; Youssoufian H; Witte L; Samakoglu S; Schwartz J; Surguladze D; Tonra JR
Neoplasia; 2011 Jan; 13(1):49-59. PubMed ID: 21245940
[TBL] [Abstract][Full Text] [Related]
19. High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies.
Taylor M; Rössler J; Geoerger B; Laplanche A; Hartmann O; Vassal G; Farace F
Clin Cancer Res; 2009 Jul; 15(14):4561-71. PubMed ID: 19605404
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.
Yuasa T; Takahashi S; Hatake K; Yonese J; Fukui I
Cancer Sci; 2011 Nov; 102(11):1949-57. PubMed ID: 21812860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]